Cargando…

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout

The aim of this review is to present current evidence about the efficacy and safety of lesinurad in combination with xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricemia in patients with gout. Gout is the most common inflammatory form of arthritis. It is caused by an elevated concent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Ruiz, Fernando, Jansen, Tim, Tausche, Anne-Katrin, Juárez-Campo, Mónica, Gurunath, Ravichandra Karra, Richette, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544139/ https://www.ncbi.nlm.nih.gov/pubmed/31191704 http://dx.doi.org/10.7573/dic.212581

Ejemplares similares

Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor Therapy
por: Perez-Ruiz, Fernando, et al.
Publicado: (2019)

Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality
por: Pérez Ruiz, Fernando, et al.
Publicado: (2019)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

Patient considerations in the management of gout and role of combination treatment with lesinurad
por: Claus, Liza W, et al.
Publicado: (2018)

Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study
por: Alghamdi, Youssef Saeed, et al.
Publicado: (2020)

Hidden gout- Ultrasound findings in patients with musculo-skeletal problems and hyperuricemia
por: Reuss-Borst, Monika A, et al.
Publicado: (2014)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Lesinurad: A significant advancement or just another addition to existing therapies of gout?
por: Gupta, Ajay, et al.
Publicado: (2016)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad
por: Jones, Graeme, et al.
Publicado: (2017)

The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout
por: Baumgartner, Scott, et al.
Publicado: (2018)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

Guideline development for the management of gout: role of combination therapy with a focus on lesinurad [Corrigendum]
Publicado: (2017)

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
por: Dalbeth, Nicola, et al.
Publicado: (2017)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Atypical musculoskeletal manifestations of gout in hyperuricemia patients
por: Sakti, Muhammad, et al.
Publicado: (2019)

Gout. Novel therapies for treatment of gout and hyperuricemia
por: Terkeltaub, Robert
Publicado: (2009)

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)

Susceptibility genes of hyperuricemia and gout
por: Nian, Yue-Li, et al.
Publicado: (2022)

Lesinurad: what the nephrologist should know
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

Computational Lexical Analysis of the Language Commonly Used to Describe Gout
por: Lawrence Edwards, N., et al.
Publicado: (2016)

Efficacy and safety of ozonated autohemotherapy in patients with hyperuricemia and gout: A phase I pilot study
por: LI, LIAN-YUN, et al.
Publicado: (2014)

An update on the genetic architecture of hyperuricemia and gout
por: Merriman, Tony R
Publicado: (2015)

Pharmacological effects of Chatuphalatika in hyperuricemia of gout
por: Sato, Vilasinee Hirunpanich, et al.
Publicado: (2018)

The role of the Mediterranean diet in hyperuricemia and gout
por: Stamostergiou, Julie, et al.
Publicado: (2018)

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey, et al.
Publicado: (2016)

Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012)

Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
por: Bardin, Thomas, et al.
Publicado: (2017)

A concise history of gout and hyperuricemia and their treatment
por: Nuki, George, et al.
Publicado: (2006)

Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia
por: Cao, Ling, et al.
Publicado: (2021)

Why Does Hyperuricemia Not Necessarily Induce Gout?
por: Zhang, Wei-Zheng
Publicado: (2021)

The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics
por: Wu, Xinghong, et al.
Publicado: (2023)

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey N., et al.
Publicado: (2016)

The development of an effective synthetic route of lesinurad (RDEA594)
por: Meng, Qing, et al.
Publicado: (2017)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Circulating microRNA alternations in primary hyperuricemia and gout
por: Bohatá, Jana, et al.
Publicado: (2021)

Treatment for hyperuricemia and gout in Japan: Aspect of prescription and duration
por: Zhang, Di
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pb2qsaulht4srdmqbgkti0bve3